The EPS projection of Allergan, Inc. (NYSE:AGN) for quarter ended 2016-09-30 is $3.65. Last week, the EPS forecast was $3.65 against target of $3.65, a month earlier. Two months ago, this estimate was $3.65 versus forecast of $3.65 three months earlier, implying a deviation of 0%.
Allergan, Inc. (NYSE:AGN) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 2.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 4, 3, and 4, correspondingly.
EPS estimate downgrade for Allergan, Inc. (NYSE:AGN) in the preceding 30, 120, 60 and 90 days were 0, 2, 3, and 2, correspondingly.
Allergan, Inc. (NYSE:AGN) EPS target for the quarter closed 1 was $3.65, based on 9 recommendations. As reported on 2016-05-10 the EPS was $3.04. The change was $0.05, implying a percentage deviation of 1.67%. The projections showed a standard deviation of 0.1.
Quarterly Sales Estimates
Allergan, Inc. (NYSE:AGN) yearly sales prediction for the fiscal 2016 stands at $4618.166 and the median estimate is at $4660.5. Almost 3 analysts issued sales target.
Highest sales target is $4672 while the lowest target is $4522 showing standard deviation of 83.481%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. Allergan, Inc. (NYSE:AGN) announced that the deviation in forecast was 2.648%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...